EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and safety of single antiplatelet therapy with anticoagulation in patients with AMI–cardiogenic shock requiring VA-ECMO

Junad M Chowdhury iD, Michelle Ferri, Mary Looby, Abhimanyu Chandel, Mehul Desai, Lauren Albertina, Michelle Gannon, Karl D Young, Evan Franke, Kimberly Barker, Lindsay Clevenger, Thomas Brad Lee und 7 weitere

Perfusion · 10.06.2026

DOI: 10.1177/02676591261459249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Perfusion, online erschienen am 10.06.2026. Verfasst von Junad M Chowdhury und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Critical Care Services, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, VA, USA. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with stenting is standard of care but increases bleeding risk, particularly in patients requiring veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for acute myocardial infarction–cardiogenic shock. Evidence guiding optimal antithrombotic strategies in this high-risk population remains limited.

Methods

We conducted a retrospective observational study at a high-volume ECMO center. From January 2018 to December 2022, 351 VA-ECMO patients were screened, and 72 who underwent PCI immediately prior to or during ECMO were included. Patients were grouped by initial post-PCI antiplatelet strategy: aspirin alone (n = 33), augmented therapy (n = 25), or no antiplatelet therapy (n = 14). The primary objective was to evaluate the safety and efficacy of an aspirin-only strategy for preventing in-stent thrombosis. Efficacy was assessed by the incidence of in-stent thrombosis during ECMO hospitalization, and safety was assessed by the occurrence of major bleeding events.

Results

Groups were similar in age, race, gender, and BMI. No patient developed clinically overt in-stent thrombosis. Major bleeding occurred in 33.3% of aspirin, 48% of augmented, and 50% of no-antiplatelet patients (p = 0.396). Most common bleeding events were hemoptysis, intracranial hemorrhage, and gastrointestinal bleeding.

Conclusions

Among patients undergoing PCI with concurrent VA-ECMO support, no differences in stent thrombosis or major bleeding were observed between aspirin monotherapy, augmented antiplatelet therapy, or no antiplatelet therapy. However, intracranial hemorrhage occurred more frequently in the Augmented AP group. These findings suggest that aspirin monotherapy may provide adequate protection against stent thrombosis while potentially minimizing bleeding risk in this critically ill population.

Schlagwörter

Stichwörter der Autor:innen

ECMOPCIdual antiplatelet therapyin stent thrombosis

Autor:innen und Institutionen

  • Division of Medical Critical Care Services, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, VA, USA.
  • Advanced Lung Disease and Transplant Clinic, Inova Schar Heart and Vascular, Falls Church, VA, USA.
  • Department of Pharmacy, Inova Fairfax Medical Campus, Falls Church, VA, USA.
  • Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
  • Division of Cardiovascular Critical Care, Advent Health, Orlando, FL USA.
  • Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, VA, USA.

ORCID-Profile: Junad M Chowdhury

Zitieren

APA

Chowdhury, J. M., Ferri, M., Looby, M., Chandel, A., Desai, M., Albertina, L., Gannon, M., Young, K. D., Franke, E., Barker, K., Clevenger, L., Lee, T. B., Tehrani, B. N., Singh, R., Vavilin, I., Alkalbani, M., King, C. S., Vandenbriele, C., & Truesdell, A. G. (2026). Efficacy and safety of single antiplatelet therapy with anticoagulation in patients with AMI–cardiogenic shock requiring VA-ECMO. Perfusion. https://doi.org/10.1177/02676591261459249

Vancouver

Chowdhury JM, Ferri M, Looby M, Chandel A, Desai M, Albertina L, et al. Efficacy and safety of single antiplatelet therapy with anticoagulation in patients with AMI–cardiogenic shock requiring VA-ECMO. Perfusion. 2026. doi:10.1177/02676591261459249

BibTeX
@article{Chowdhury2026,
  author = {Chowdhury, Junad M and Ferri, Michelle and Looby, Mary and Chandel, Abhimanyu and Desai, Mehul and Albertina, Lauren and Gannon, Michelle and Young, Karl D and Franke, Evan and Barker, Kimberly and Clevenger, Lindsay and Lee, Thomas Brad and Tehrani, Benham N and Singh, Ramesh and Vavilin, Ilan and Alkalbani, Mutaz and King, Christopher S and Vandenbriele, Christophe and Truesdell, Alexander G},
  title = {Efficacy and safety of single antiplatelet therapy with anticoagulation in patients with AMI–cardiogenic shock requiring VA-ECMO},
  journal = {Perfusion},
  year = {2026},
  doi = {10.1177/02676591261459249}
}
Kostenlos starten →